Garde Capital Inc. buys 300 shares of Johnson & Johnson (NYSE:JNJ)


Garde Capital Inc. increased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,084 shares of the company, after purchasing an additional 300 shares during the period. The interests of Garde Capital Inc. in Johnson & Johnson were worth $327,000 at the end of the most recent reporting period.

A number of other institutional investors have also been buying and selling shares of the stock recently. Norges Bank purchased a new position in Johnson & Johnson in the fourth quarter worth approximately $4,071,642,000. Charles Schwab Investment Management Inc. expanded its stake in Johnson & Johnson by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 15,945,533 shares of the company’s stock worth $2,483,532,000 after purchasing an additional 241,799 shares during the period. California Public Employees Retirement System grew its stake in Johnson & Johnson by 4.9% in the fourth quarter. California Public Employees Retirement System now owns 10,620,264 shares of the company’s stock worth $1,664,620,000 after purchasing an additional 498,647 shares during the period. Dimensional Fund Advisors LP grew its holdings in Johnson & Johnson by 10.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 10,169,190 shares of the company’s stock worth $1,593,908,000 after purchasing an additional 975,485 shares during the period. Finally, Clearbridge Investments LLC grew its holdings in Johnson & Johnson by 0.8% in the fourth quarter. Clearbridge Investments LLC now owns 6,285,184 shares of the company’s stock worth $985,140,000 after purchasing an additional 50,822 shares during the period. 69.55% of the shares are held by institutional investors.

Johnson & Johnson is trading 0.1% higher

Shares of JNJ opened at $145.54 on Friday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The company’s 50-day moving average is $148.38 and its 200-day moving average is $154.67. The stock has a market cap of $350.27 billion, a price-to-earnings ratio of 9.07, a price-to-earnings ratio of 2.42 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly results on Tuesday, April 16. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same period last year, the company earned $2.68 in earnings per share. The company’s quarterly revenue rose 2.3% year over year. Research analysts expect Johnson & Johnson to post 10.63 earnings per share for the current year.

Johnson & Johnson increases dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4. Shareholders of note on Tuesday, May 21st received a dividend of $1.24. The ex-dividend date of this dividend was Monday, May 20. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a dividend of $4.96 annually and a yield of 3.41%. Johnson & Johnson’s dividend payout ratio (DPR) currently stands at 30.92%.

Wall Street analysts weigh in

A number of equity research analysts have weighed in on JNJ stock. Bank of America lowered their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, May 6. StockNews.com downgraded shares of Johnson & Johnson from a “strong buy” rating to a “buy” rating in a report on Monday, June 10. Finally, Morgan Stanley lowered their price target on shares of Johnson & Johnson from $168.00 to $167.00 and gave the stock an “equalweight” rating in a report on Wednesday, April 17. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of ‘Hold’ and an average price target of $174.07.

Check out our latest report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, produces and sells various healthcare products worldwide. The company’s Innovative Medicine segment offers products across several therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension, including pulmonary arterial hypertension, through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Read further

Would you like to see which other hedge funds own JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Quarterly Institutional Ownership for Johnson & Johnson (NYSE:JNJ)



Get daily news and reviews for Johnson & Johnson – Enter your email address below to receive a daily digest of the latest news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.